Real-world use of Grassmuno® for grass pollen allergy
Official title: Eine Prospektive, Offene, Multizentrische, Nicht-interventionelle Studie Zur Erhebung Von Daten Zur Anwendung Von Grass MATA MPL 27 600 SU Und Compliance in Der täglichen Klinischen Praxis Bei Erwachsenen Gräserpollen- Allergikern
Run by Allergy Therapeutics · NCT07412990 · Data updated 2026-11-12
This project will collect real-world information on how Grassmuno® works for adults with moderate to severe grass pollen allergy.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | Allergy Therapeutics Industry-sponsored |
| Locations | 1 site (Hamburg) |
| Status | Recruiting |
| Started | March 11, 2026 |
| Main results expected | October 2, 2028 |
| Study ends | October 2, 2028 |
| Registry record updated | March 20, 2026 |
| Trial ID | NCT07412990 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with IgE-mediated moderate to severe grass pollen–induced rhinitis or rhinoconjunctivitis who have already been prescribed Grassmuno® per its SmPC and who can read and understand German.
✕Probably not a fit
Patients who are under 18, who have contraindications listed in the SmPC, who cannot understand German, or who have uncontrolled asthma are unlikely to be eligible or to benefit from the study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a non-interventional, observational collection of routine clinical data from adults treated with Grassmuno® according to the product label. Patients are enrolled only after the treating physician has already decided to prescribe Grassmuno® and will be followed during ordinary care. The study records treatment use, tolerability, adverse events, symptom control, and any concomitant medications. Participation is at physician discretion and excludes patients with SmPC contraindications or those who cannot adequately understand German.
Why it matters
Potential benefit: If successful, the data could help doctors and patients understand how well Grassmuno® works and how safe it is in everyday clinical practice.
How similar studies have gone: Allergen immunotherapy for grass pollen has demonstrated efficacy and safety in randomized trials, but real-world observational data specific to Grassmuno® are more limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who * are male and female patients * are 18 years of age or older * treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen. * Patients will only be enrolled in the study after the treatment decision has been made Exclusion Criteria: At the physician's discretion, the study should not be offered to the following patients: * Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents. * In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.
Where it's running
-
Dr. Kasche
Hamburg, Germany Recruiting
Study contacts
- Study coordinator: Ralph Mösges, Univ. Prof. Dr. med. Dipl.-Ing
- Email: Ralph.Moesges@Uni-Koeln.de
- Phone: +49 172 2056 230
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Creating a risk assessment tool for thunderstorm asthma (CARISTA)
This project will test whether lung tests, allergy blood markers and daily symptom tracking can predict which adults with hay fever in South‑Eastern Australia will have seasonal or thunderstorm-related asthma attacks over two spring seasons.
-
Intralymphatic immunotherapy with Vitamin D for grass pollen allergies
This study is testing if a new treatment using Vitamin D with intralymphatic immunotherapy can help people with grass pollen allergies feel better during allergy season.
-
Testing B-regulatory Cells as a Marker for Allergen Immunotherapy Response
This study tests whether changes in blood B-regulatory cells can signal successful allergen immunotherapy in adults with pollen, dust mite, or insect venom allergies.
-
Effects of nitrogen pollution on pollen allergies in Belgium
This study is testing how nitrogen pollution affects allergy symptoms in people who are sensitive to pollen in Belgium.
-
Standardizing allergen extracts from Quercus ilex and Quercus robur
This study is testing how strong allergen extracts from two types of oak trees are to help people with allergies by using skin tests and blood samples.
-
Safety and tolerability of DM-101PX in birch pollen allergy
This early-stage trial tests whether DM-101PX is safe and tolerable in adults with birch pollen allergy, compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.